Coastal Bridge Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Coastal Bridge Advisors’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,870	Closed	-$12K	–	67
2016 Q2	$12K	Hold	2,870	–	–	0.01%	64
2016 Q1	$16K	Buy	+2,870	New	+$37.3K	0.01%	61

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Coastal Bridge Advisors's OREX Position: Q3 2016 in Review

Coastal Bridge Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 2,870 shares — an estimated $12K sold.

Coastal Bridge Advisors first reported a position in OREX in Q1 2016 and held it in 2 quarters. The position peaked at $16K in Q1 2016. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

Coastal Bridge Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Coastal Bridge Advisors sold 2,870 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $12K.
Coastal Bridge Advisors first reported a position in Orexigen Therapeutics, Inc. in Q1 2016 and held it in 2 quarters.
Coastal Bridge Advisors's Orexigen Therapeutics, Inc. position peaked at $16K in Q1 2016.
55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Coastal Bridge Advisors's 13F filing for Q3 2016, filed 9 Nov 2016.